Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Inhalation serrapeptase preparation

A technology of serrapeptase and inhalation drug delivery, which is applied in the field of medicine and can solve problems such as low bioavailability, slow onset of action, and unsatisfactory therapeutic effect

Inactive Publication Date: 2012-04-18
FUKANGREN BIO PHARMA
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Adults take 1-2 tablets 3 times a day after meals, the onset of action is slow, the bioavailability is low, and the therapeutic effect is not ideal

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Inhalation serrapeptase preparation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0008] Aerosol for inhalation:

[0009] Recipe and process: Take the main medicine into micropowder, the particle size D90 is less than 10 microns, weigh 0.5g of the micronized powder, put it into aluminum cans, lock the metering valve, and fill it with 12g of tetrafluoroethane. Shake well before use, each press 100μl, containing 5mg of main medicine.

Embodiment 2

[0011] Powder mist for inhalation:

[0012] Prescription and process: take the main drug into micronized powder, the particle size D90 is less than 10 microns, weigh 5g of the micronized powder, 150g of lactose for aseptic inhalation, mix well in a sterile environment, and fill in the No. 3 capsule shell, and the preparation is complete. 1000 tablets. Put 1 capsule into a special inhalation device before use and set aside. Each capsule shell contains 5mg of the main drug.

Embodiment 3

[0013] Example 3: Influence on airway inflammation

[0014] Experimental method: 40 rats were randomly divided into two groups, 20 rats in each group. They are the oral administration group (group A) and the inhalation administration group (group B). Group A is randomly divided into: blank control group (A0) and oral serrapeptase group (A1), group B is randomly divided into They are: blank control group (B0) and oral serrapeptase group (B1). In each group, 1 mg / kg lipopolysaccharide was injected into the tube on the 1st and 20th day of the experiment, and the rats were put into a 80cm×60cm×58cm plexiglass box for passive smoking on the 2nd to 19th and 21st to 40th days, twice a day (interval 4h ), each lasting 1h (10 cigarettes). Each treatment group was given corresponding treatment drugs on the 2nd to 19th and 21st to 40th days. Inhalation group: Therapeutic drug + 5ml physiological saline, inhaled at 5L / min in aerosol, (placed in a 30cm×30cm×20cm glass box), 3 times / d, 25mi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle sizeaaaaaaaaaa
particle diameteraaaaaaaaaa
Login to View More

Abstract

The invention discloses an inhalation serrapeptase preparation. The inhalant serrapeptase preparation comprises but is not limited to inhalation aerosol powder, and inhalation aerosol. In the inhalation serrapeptase preparation, serrapeptase is micronized, and the particle size is 1 to 100 microns, preferably 3 to 50 microns. The serrapeptase preparation can be inhaled to treat inflammation, edema and expectoration difficulty which are caused by various respiratory diseases.

Description

Technical field [0001] The present invention is a serrapeptase preparation for administration by inhalation, and belongs to the technical field of medicine. Background technique [0002] Serrapeptidase is a proteolytic enzyme. It has a strong effect of dissolving fibrin mass, eliminating mucus purulent sputum and purifying inflammatory lesions. It is widely used clinically for the difficulty of expectoration caused by respiratory diseases. Serrapeptidase can reduce phlegm, reduce inflammation, and eliminate edema or swelling: its mechanism is to degrade abnormal exudates, denatured proteins and cellulose clots to make pus, sputum, blood clots and other liquefaction thinner. Easy to drain and discharge; promote the absorption of decomposition products by blood vessels and lymphatic vessels, thereby improving the circulation of inflammatory lesions, eliminating swelling, and promoting the regeneration of granulation tissue, thereby achieving the effect of treating both symptoms and...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/48A61K9/72A61P11/10A61P11/00
Inventor 不公告发明人
Owner FUKANGREN BIO PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com